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Protein–protein interactionLectin-like oxidized low-density lipoprotein receptor (LOX-1) is a scavenger receptor that binds oxi-
dized low-density lipoprotein (OxLDL) and has a role in atherosclerosis development. The N-termi-
nus intracellular region (cytoplasmic domain) of LOX-1 mediates receptor internalization and
trafﬁcking, potentially through intracellular protein interactions. Using afﬁnity isolation, we iden-
tiﬁed 6 of the 8 components of the chaperonin-containing TCP-1 (CCT) complex bound to LOX-1
cytoplasmic domain, which we veriﬁed by coimmunoprecipitation and immunostaining in human
umbilical vein endothelial cells. We found that the interaction between CCT and LOX-1 is direct and
ATP-dependent and that OxLDL suppressed this interaction. Understanding the association between
LOX-1 and the CCT complex may facilitate the design of novel therapies for cardiovascular disease.
Structured summary of protein interactions:
LOX-1physically interacts with CCT1 by pull down (View interaction)
LOX-1physically interacts with CCT1 by anti bait coimmunoprecipitation (View interaction)
LOX-1, M6PR1 and CCT1colocalize by ﬂuorescence microscopy (View interaction)
LOX-1physically interacts with CCT1, CCT3, CCT7, CCT5, CCT4 and CCT6A by pull down (View interaction)
CCT1, LOX-1 and EEA1 colocalize by ﬂuorescence microscopy (View interaction)
CCT1 and LOX-1 colocalize by ﬂuorescence microscopy (View interaction)
LOX-1 physically interacts with CCT4 by anti bait coimmunoprecipitation (View interaction)
LOX-1 binds to CCT1 by pull down (View interaction)
LOX-1 binds to CCT4 by pull down (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Atherosclerosis is a complex inﬂammatory disease of the vessel
wall [1]. The development of atherosclerotic plaque is caused, in
part, by the progressive internalization and accumulation of mod-
iﬁed lipids, particularly oxidized low-density lipoprotein (OxLDL)
[2]. OxLDL is bound and internalized into cells by the C-type lec-
tin-like OxLDL receptor (LOX-1) [3], which has been shown to play
a signiﬁcant role in atherogenesis [4]. LOX-1 is a type II transmem-
brane protein expressed on endothelial cells, monocytes,mooth muscle cells, and platelets. As a scavenger receptor, LOX-1
also binds to C-reactive protein [5], heat shock proteins [6],
apoptotic cells [7], platelets [8], and bacteria [9]. LOX-1 has been
associated with not only atherosclerotic disease [4] but also
Alzheimer’s disease [10,11] and sepsis [12]. Because of the multi-
functional properties of LOX-1, it has been considered an attractive
therapeutic target for treating a variety of diseases [13–16].
Upon binding to OxLDL, LOX-1 can induce several cellular
events [15,17,18]. In association with membrane type 1 matrix
metalloproteinase, LOX-1 signaling can promote endothelial dys-
function through the activation of the small GTPases RhoA and
Rac1 [19]. LOX-1 signaling can also promote pro-inﬂammatory
changes in endothelial cells through the activation of NFjB [20],
resulting in increased expression of adhesion molecules [21] and
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[22]. In addition, LOX-1 signaling can result in apoptosis due to
the activation of protein kinase C and other protein tyrosine
kinases [23]. Although there are numerous mechanisms through
which LOX-1 signaling has been linked to cardiovascular disease,
little is known regarding the membrane-proximal events in LOX-
1 receptor signaling.
The cytoplasmic domain of LOX-1 has been shown to play a
critical role in receptor trafﬁcking and endocytosis [24] and in
cell-surface sorting [25]. A recent study has also shown that intra-
cellular proteins ROCK2 and ARHGEF1 can form a complex with
LOX-1 in an OxLDL-dependent manner [26]. Moreover, a naturally
occurring, alternatively spliced isoform of LOX-1, termed LOXIN,
has been shown to act as a dominant negative regulator of LOX-1
[27]. Although LOXIN has defective ligand-binding abilities, it has
an intact transmembrane and intracellular domain that can form
a heterodimer with intact LOX-1 [28]. Together, these reports sug-
gest that the cytoplasmic domain of LOX-1 is an important media-
tor of LOX-1 function. Because the cytoplasmic tail of LOX-1 has no
known enzymatic or catalytic activity, intracellular signaling prob-
ably requires interaction between the LOX-1 cytoplasmic domain
and intracellular proteins. To our knowledge, no intracellular pro-
teins have been identiﬁed that directly interact with the LOX-1
cytoplasmic domain [29].
In this study, we performed afﬁnity isolation experiments using
a LOX-1 cytoplasmic domain peptide to identify intracellular pro-
teins that interact with the LOX-1 cytoplasmic domain. The identi-
ﬁcation of such proteins may help to determine ways to regulate
the function of LOX-1 in disease.2. Materials and methods
2.1. Cell culture
HUVECs were cultured in EGM-2 (Lonza, Houston, TX) supple-
mented with 10% (v/v) FBS (Gibco, Grand Island, NY), penicillin
(100 units/ml), and streptomycin (100 lg/ml) (Gibco). Cells were
grown at 37 C in humidiﬁed conditions with 5% CO2. Before use,
cells were trypsinized by using 0.05% Trypsin/EDTA (Gibco), col-
lected, and washed in phosphate-buffered saline (PBS).
2.2. Peptides
A LOX-1 cytoplasmic domain peptide (amino acid residues 1–
33) was synthesized with C-terminal modiﬁcations that included
a dual glycine spacer, a penultimate lysine-long chain biotin (LC-
Biotin), and a C-terminal glycine (sequence shown in Fig. 1). For
a control, we used a scrambled LOX-1 cytoplasmic domain peptide
generated with the same C-terminal modiﬁcations (sequence
shown in Fig. 1). The peptides were synthesized, puriﬁed by using
high-performance liquid chromatography (>90%), and veriﬁed by
mass spectrometry (NeoBioscience, Cambridge, MA).
2.3. Cell lysate preparation
HUVECs were washed with PIPES buffer, which comprised
10 mM PIPES and 50 mM NaCl (pH 6.8), and resuspended
(10  106 cells/ml) in PIPES lysis buffer, which consisted of PIPES
buffer containing 1% Triton X-100, 1 mM EDTA, 1 mM Na3VO4,
50 mM NaF, 150 mM sucrose, protease inhibitors (i.e., mini-tablets
containing inhibitors of chymotrypsin, thermolysin, papain, pron-
ase, pancreatic extract, and trypsin; Roche, Indianapolis, IN), and
0.1 mM N-ethylmaleimide (Sigma, St Louis, MO). The cells were
incubated overnight in the lysis buffer at 4 C with end-over-end
rotation. Lysates were then passed through a 21-gauge syringeand centrifuged at 13000g for 30 min at 4 C. Lysate protein con-
centrations were determined by using Quick Start Bradford Dye
reagent (Bio-Rad, Hercules, CA).
2.4. Afﬁnity isolation using LOX-1 cytoplasmic domain peptide
Afﬁnity isolation assays were performed as previously
described [30], with modiﬁcations. NeutrAvidin agarose beads
(100 ll of 50% slurry; Thermo Scientiﬁc, Rockford, IL) were washed
in PIPES buffer. Then, 150 lg of LOX-1 cytoplasmic domain peptide
or control scrambled peptide was added to the beads in a ﬁnal vol-
ume of 1 ml in PIPES buffer. After an overnight incubation at 4 C,
FBS (20% v/v) was added to block nonspeciﬁc binding sites, and the
beads were again incubated overnight at 4 C. The peptide-bound
beads were then thoroughly washed in PIPES buffer for use in
the afﬁnity isolation assay. Between 500 and 700 lg (total protein)
of HUVEC lysate was added to 100 ll of either unbound beads or
peptide-bound beads, and the binding volume was adjusted to
1 ml with PIPES lysis buffer. After an overnight incubation at
4 C, the beads were washed 5 times with PIPES lysis buffer and
collected by centrifugation at 700g for 2 min. To elute the bound
proteins, the collected beads were then heated at 95 C in 75 ll of
2 sodium dodecyl sulfate (SDS) sample buffer (125 mM Tris HCl
[pH 6.8], 20% glycerol, 4% SDS, and 0.005% bromophenol blue) for
5 min and centrifuged at 13000g for 1 min. The solubilized pro-
teins were then separated by 4–20% Precise™ protein gels (Thermo
Scientiﬁc).
2.5. Silver staining and LC/MS/MS analysis
The protein samples obtained by afﬁnity isolation and run on
Precise protein gels (4–20%) were stained by using the Pierce Silver
Staining kit (Thermo Scientiﬁc). Protein bands that were visible in
the lanes with the LOX-1 afﬁnity isolation products were excised,
destained as per the manufacturer’s protocol, and sent to the Uni-
versity of Utah Mass Spectrometry and Proteomics core facility for
analysis by liquid chromatography combined with tandem mass
spectrometry (LC/MS/MS). In-gel digestion and LC/MS/MS analysis
of these samples were performed as previously described [31].
2.6. Coimmunoprecipitation assay
HUVECs were treated with or without 10 lg/ml of OxLDL
(770252-7, Kalen Biomedical, Montgomery Village, MD) for 1 h,
lysed by using the previously described method in Section 2.3,
and then incubated overnight at 4 C with 1 lg of anti-LOX-1
monoclonal antibody (sc66155, Santa Cruz Biotechnology, Dallas,
TX) or isotype-speciﬁc (IgG1) control antibody (0102-01, Southern-
Biotech, Birmingham, AL). Next, 20 ll Protein-G beads (GE Health-
care, Pittsburgh, PA) prewashed in PIPES buffer was added to the
cell lysate and rotated for 2 h at 4 C. The beads were then washed
5 times with PIPES lysis buffer, and the proteins were eluted by
adding 2 SDS sample buffer (40 ll) and heating the beads at
95 C for 5 min. Eluted proteins were separated by 4–20% Precise™
protein gels (Thermo Scientiﬁc), and Western blot analysis was
performed by using anti-CCT1 (sc53454, Santa Cruz Biotechnology)
or anti-CCT4 (sc137094, Santa Cruz Biotechnology) antibodies.
2.7. Indirect immunoﬂuorescence confocal microscopy
HUVECs (2  105 cells) were cultured in supplemented EGM-2
medium on sterile 12-mm glass cover slips in a 12-well plate over-
night at 37 C in humidiﬁed conditions with 5% CO2. The following
day, cells were incubated with or without 10 lg/ml of DiI-OxLDL
(Kalen Biomedical) for 1 h and washed in PBS twice before under-
going ﬁxation with 3.7% paraformaldehyde for 15 min at room
Fig. 1. Primary structure of the LOX-1 receptor. LOX-1 is a type II transmembrane protein with a short (33 amino acid) N-terminal intracellular domain, or cytoplasmic tail
(CT), a single-pass transmembrane domain (TM), a neck region, and a C-terminal ligand-binding domain (LBD) (top image). The sequences of the LOX-1 cytoplasmic domain
peptides and the scrambled LOX-1 peptides used in the afﬁnity isolation experiments are shown with the penultimate lysine-long chain biotin (LC-Biotin) modiﬁcations
(bottom image).
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taining 10% horse serum and 0.2% Triton X-100 for 10 min on ice.
The cells were blocked overnight at 4 C with SuperBlock blocking
buffer (Thermo Scientiﬁc) supplemented with 5% horse serum and
5% goat serum. For immunostaining, 100 ll of primary antibody
(diluted to 1 lg/ml in blocking buffer supplemented with 0.05%
Tween 20 and 0.001% Triton X-100) was pipetted onto ﬂattened
paraﬁlm, and a cover slip containing the cells was placed over it.
After a 45-min incubation at room temperature under humidiﬁed
conditions, the cover slips were removed, placed in wells of a 6-
well plate, and washed 3 times for 10 min each with PBS contain-
ing 10% horse serum, 0.05% Tween 20, and 0.001% Triton X-100.
The cells were then immunostained with isotype-speciﬁc second-
ary antibodies (2–4 lg/ml) in a fashion similar to that used forFig. 2. Identiﬁcation of proteins that interact with the LOX-1 cytoplasmic domain. (A) A b
experiments to identify proteins that interact with the LOX-1 cytoplasmic domain. A scra
bound to NeutrAvidin agarose beads for the assay. After blocking, the beads were incuba
eluted off the beads with SDS sample buffer. (B) A gel showing the eluted proteins separa
asterisks) were excised and analyzed by liquid chromatography with tandem mass spect
cytoplasmic domain peptide.the primary antibodies. Primary antibodies included anti-LOX-1
(ab60178, Abcam, Cambridge, MA) and anti-CCT1 (sc53454, Santa
Cruz Biotechnology), and their respective secondary antibodies
were Alexa Fluor 488 goat anti-rabbit (Invitrogen, Carlsbad, CA)
and Alexa Fluor 555 goat anti-rat (Invitrogen). Isotype-speciﬁc
IgG and the respective secondary antibody were used as a control.
Immunostaining for multiple proteins was performed in series,
with the primary antibody or control isotype-speciﬁc IgG being fol-
lowed by the respective secondary antibodies. Lastly, to aid in the
visualization of the nuclei, Hoechst 33258 (Sigma) was diluted to
2 lg/ml in blocking buffer with 0.05% Tween 20 and 0.001% Triton
X-100 and added to the ﬁxed cells. After incubating the cells for
10 min at room temperature, the cells were washed extensively.
The cover slip with the cells was then placed over a drop ofiotinylated LOX-1 cytoplasmic domain peptide was used as bait in afﬁnity isolation
mbled biotinylated LOX-1 peptide was used as a control. Biotinylated peptides were
ted with HUVEC lysate at 4 C. The beads were then washed, and bound protein was
ted by SDS–PAGE and silver stained. Proteins that were bound to LOX-1 (shown by
rometry. B, beads alone; L, LOX-1 cytoplasmic domain peptide; sL, scrambled LOX-1
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Fig. 3. Interaction between the CCT complex and the LOX-1 cytoplasmic domain. (A) Western blot analysis of the afﬁnity isolation products showing that both CCT1 and CCT4
speciﬁcally bound to the LOX-1 peptide but not to the beads alone or to the scrambled LOX-1 peptide (top panel). Peptide loading was visualized with Ponceau staining of
blots (lower panel, just below the 10 kDa molecular weight marker). CL, cell lysate of HUVECs; B, beads alone; L, LOX-1 cytoplasmic domain peptide; sL, scrambled LOX-1
cytoplasmic domain peptide; IB, immunoblotting. (B) Western blot analysis of the proteins immunoprecipitated from HUVECs showing that the CCT complex subunits CCT1
(top) and CCT4 (bottom) coimmunoprecipitated with the proteins captured by the LOX-1-speciﬁc mouse monoclonal antibody (LOX) but not with those captured by the IgG1
isotype control antibody (Iso). Blots shown are representative of at least 4 independent experiments. In the top panel, the light chain (IgG-L) of the LOX-1 mAb and the
isotype-matched control mAb can be seen at approximately 25 kDa in both lanes. In the bottom panel, both the IgG heavy chain (IgG-H) and IgG-L of the LOX-1 monoclonal
antibody and the isotype control antibody are visible at approximately 55 kDa and 25 kDa, respectively. CL, cell lysate of HUVECs. IP, immunoprecipitation; IB,
immunoblotting. (C) Immunoﬂuorescence staining of HUVECs shows the colocalization of LOX-1 and CCT-1 in small, vesicular-like structures (white vesicles shown by
arrows in merged image of LOX-1 and CCT1). Nuclei were stained with Hoechst 33258 (blue), and all images were acquired by using a Leica TCS SP5 II confocal microscope.
Colocalization imaging was performed by scanning an XY plane at a single Z position.
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frost slide and left to dry at room temperature for 15 min. The
slides were stored in a cold room until confocal microscopy was
performed. Similar methods were used to label early and late
endosomes with anti-EEA1 (Early Endosome Antigen-1 antibody,
sc-365652; Santa Cruz Biotechnology) and anti-M6PR1 (Mannose
6-Phosphate Receptor antibody [2G11], MA1-066; Thermo Scien-
tiﬁc), respectively. All images were obtained by using a Leica TCS
SP5 II confocal microscope. Colocalization imaging was performed
by scanning an XY plane at a single Z position. Identical settings
were used for both control and test slides.
2.8. Chaperonin-containing TCP-1 (CCT) complex puriﬁcation
CCT was puriﬁed from bovine testes according to previously
established procedures, and the integrity of the oligomeric CCT
complex was conﬁrmed by using single-particle cryo-electronmicroscopy [32,33]. The ﬁnal puriﬁed protein concentration was
determined by using the Bradford assay with BSA standards
(Pierce), and substrate folding activity of the CCT complex was
assessed with a luciferase refolding assay, as previously described
[34].
2.9. Direct binding assay
NeutrAvidin agarose beads (100 ll of 50% slurry, Thermo Scien-
tiﬁc) were washed in CCT lysis buffer, which comprised 25 mM
HEPES (pH 7.4), 100 mM KCl, 5 mM MgCl2, 10% glycerol, 0.1% Tri-
ton X-100, 20 mM EDTA, 0.1% v/v Tween-20, and protease inhibi-
tors (Roche). Then, 100 lg of the biotinylated LOX-1 peptide or
the control scrambled peptide was added to 100 ll of the resus-
pended beads, and the CCT lysis buffer was used to bring the ﬁnal
volume to 1 ml. After an overnight incubation at 4 C, the peptide-
bound beads were washed once in CCT lysis buffer, and the
10
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Fig. 4. Direct binding of CCT to the LOX-1 cytoplasmic domain. Puriﬁed CCT protein
from bovine testes was used in direct binding assays either in the presence (+) or
absence () of ATP (0.1 mM). The Western blot shows that CCT1 speciﬁcally bound
to the LOX-1 peptide in the presence of ATP (L+) but not to the LOX-1 peptide in the
absence of ATP (L) or to the scrambled LOX-1 peptide in presence of ATP (sL+).
Peptide loading was visualized by using Streptavidin-HRP (lower panel, just below
the 10 kDa molecular weight marker). Blots shown are representative of 3
independent experiments. IB, immunblotting.
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overnight incubation at 4 C. The blocked beads were then washed
and resuspended in 1 ml of CCT lysis buffer. Puriﬁed endogenous
CCT (100 lg) from bovine testis was then combined with the pep-
tide-bound beads and incubated overnight at 4 C in the presence
or absence of ATP (0.1 mM). After the incubation, the beads were
washed 5 times with CCT lysis buffer and collected by centrifuga-
tion at 700g for 2 min. Collected beads were heated at 95 C in
50 ll of 2 SDS sample buffer for 5 min and centrifuged at
13000g for 1 min. The eluted proteins (20 ll) were then sepa-
rated by 4–20% Precise™ protein gels (Thermo Scientiﬁc), and
Western blot analysis was performed to detect CCT1. Puriﬁed
CCT was run on the same gel as a control.
3. Results
3.1. CCT complex proteins identiﬁed as novel LOX-1 cytoplasmic
domain-interacting proteins
To identify the intracellular molecules that interact with the
LOX-1 cytoplasmic domain, we synthesized the cytoplasmic tail
of LOX-1 as a biotinylated peptide (Fig. 1), conjugated this peptide
to NeutrAvidin agarose beads, and used these beads in afﬁnity iso-
lation experiments with lysate from HUVECs (Fig. 2A). We used
beads alone and beads conjugated to a scrambled sequence of
the LOX-1 peptide as controls. The proteins eluted from the beads
after afﬁnity isolation were separated on 4–20% protein gels and
silver stained. The bands for each of the proteins enriched on the
LOX-1 peptide beads (Fig. 2B, asterisks) were excised, destained,
and subjected to LC/MS/MS analysis. The proteins identiﬁed
included 6 of the 8 subunits in the CCT complex: subunits 1, 3, 4,
5, 6A, and 7 (Supplementary Table S1).
3.2. CCT constitutively interacts with LOX-1
To verify the interactions between the LOX-1 cytoplasmic
domain and CCT complex proteins, we performed a western blot
analysis of proteins obtained by either LOX-1 afﬁnity isolation orby immunoprecipitation. For this analysis, antibodies against 2 of
the 8 subunits of the CCT complex, CCT1 (TCP1a) and CCT4
(TCP1d), were used to conﬁrm the presence of the whole CCT com-
plex [33,35]. Western blot analysis of the afﬁnity isolation products
showed CCT1 and CCT4 bound to the LOX-1 cytoplasmic domain
peptide but not to the scrambled peptide or to the beads alone
(Fig. 3A, top panels), suggesting a speciﬁc interaction between
LOX-1 and the CCT complex. Western blot analysis of the products
obtained by LOX-1 immunoprecipitation in HUVECs showed that
CCT1 and CCT4 coimmunoprecipitated with endogenous LOX-1
but not with protein bound by the isotype-matched control anti-
body, further demonstrating the speciﬁcity of the interaction
between LOX-1 and the CCT complex (Fig. 3B). Furthermore, indi-
rect immunoﬂuorescence staining of ﬁxed HUVECs showed that
LOX-1 and CCT1 colocalized in small, vesicular-like structures
(Fig. 3C). Interestingly, these vesicles were found to be partially
associated with early and late endosomes, which were identiﬁed
by using markers EEA1 and M6PR1, respectively (Supplementary
Fig. S1). These results supported the LC/MS/MS data, although they
did not indicate whether the interaction between the LOX-1 cyto-
plasmic domain and the CCT complex is direct or mediated indi-
rectly by an adaptor molecule.
3.3. CCT directly interacts with the LOX-1 cytoplasmic domain
CCT requires ATP for its activity [33,36] and to bind to intracel-
lular proteins [37–40]. Therefore, to determine whether CCT
directly interacts with LOX-1, we performed a direct binding assay
in which puriﬁed CCT was incubated with LOX-1 cytoplasmic
domain peptides in the presence or absence of ATP. As a control,
we incubated scrambled peptide with CCT in the presence of
ATP. Any bound CCT was then eluted off the beads, and Western
blot analysis was performed to detect CCT1. Fig. 4 shows that
CCT1 associated with the LOX-1 peptide in the presence of ATP
but not in the absence of ATP. In contrast, CCT1 did not bind to
the control scrambled peptide in the presence of ATP (Fig. 4). These
ﬁndings demonstrate that CCT can directly bind to the LOX-1 cyto-
plasmic domain and that this interaction is ATP-dependent.
Because CCT is known to affect the folding of some proteins [41],
we also examined whether knocking down the expression of
CCT1 would affect LOX-1 expression. In HUVECs treated with
CCT1 siRNA, LOX-1 expression was unchanged compared to that
in HUVECs treated with control siRNA (Supplementary methods
and Supplementary Fig. S2).
3.4. OxLDL suppresses the LOX-1/CCT interaction
Oxidized low-density lipoprotein is one of the LOX-1 receptor
ligands that play an important role in atherosclerosis development
[17]. To determine whether OxLDL regulates the interaction
between LOX-1 and CCT, we treated HUVECs with DiI-labeled
OxLDL (DiI-OxLDL) and immunostained the cells for LOX-1 and
CCT1. When HUVECs were cultured without OxLDL, CCT1 colocal-
ized with LOX-1 in small, vesicle-like structures (Fig. 3C). However,
in HUVECs treated with DiI-OxLDL, the colocalization of LOX-1 and
CCT1 within these vesicles decreased (Fig. 5A). To quantify the
colocalization of LOX-1 and CCT1 in the cells before and after the
OxLDL treatment, we calculated Manders’ colocalization coefﬁ-
cients M1 and M2 (Supplementary methods). Before the OxLDL
treatment, the M1 and M2 coefﬁcients were 85.3 ± 8.8% and
71.4 ± 4.3%, respectively. After the OxLDL treatment, the M1 and
M2 coefﬁcients were signiﬁcantly reduced to 19.2 ± 3.2% and
17.2 ± 1.7%, respectively (Supplementary Fig. S3). This suggests
that OxLDL may suppress the interaction between LOX-1 and
CCT. To further examine this possibility, we assessed whether
CCT complex proteins coimmunoprecipitate with LOX-1 in
LOX-1 DiI-OxLDLCCT1
10 µM
Merge
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Fig. 5. OxLDL disassociates the CCT1/LOX-1 interaction. (A) Immunoﬂuorescence staining of HUVECs treated with DiI-OxLDL (10 lg/ml) for 1 h showed that OxLDL decreased
the colocalization of LOX-1 and CCT1, as compared to that seen in untreated cells (shown in Fig. 3C). (B) Western blot analysis showing the proteins that
coimmunoprecipitated with LOX-1 in HUVECs treated with (+) or without () OxLDL. CCT1 coimmunoprecipitated with LOX-1 in the untreated cells but did not in the OxLDL-
treated cells. The 2 bands found below CCT1 at 50 and 25 kDa are the heavy chain (IgG-H) and light chain (IgG-L) of the LOX-1 monoclonal antibody, respectively. CL, cell
lysate of HUVECs; IP, antibody used for immunoprecipitation; IB, antibody used for immunoblotting.
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showed that CCT1 coimmunoprecipitated with LOX-1 in untreated
cells but not in OxLDL-treated cells (Fig. 5B). Thus, our ﬁndings
indicate that OxLDL suppressed the CCT interaction with LOX-1.
4. Discussion
LOX-1 signaling is thought to play an essential role in the initi-
ation and progression of atherosclerosis[17]. However, little is
known about the intracellular proteins that can directly bind to
the cytoplasmic domain of LOX-1. In this study, afﬁnity isolation
experiments showed that the LOX-1 cytoplasmic domain interacts
with subunits of the CCT complex in HUVECs. This LOX-1/CCT
interaction was veriﬁed by using biochemical and cell biology
methods. Furthermore, we showed that CCT1 requires ATP
to directly bind to the cytoplasmic domain of LOX-1. To ourknowledge, this is the ﬁrst report to show that an intracellular pro-
tein, CCT, can interact directly with the LOX-1 cytoplasmic domain.
The CCT complex is a large (approximately 1 mDa), ATP-depen-
dent, protein-folding apparatus that consists of 2 hetero-oligo-
meric rings stacked upon each other. Each ring is made up of 8
subunits (CCT1–CCT8) [33,36]. In our study, we used coimmuno-
precipitation and immunoﬂuorescence experiments to verify that
components of the CCT complex colocalize and interact with
LOX-1 in intact HUVECs. Thus, it is unlikely that the interaction
identiﬁed by our afﬁnity isolation experiments resulted merely
from the in vitro recognition of the LOX-1 cytoplasmic domain
peptide by CCT after cell lysis.
The CCT complex is mainly involved in the folding of cytoskel-
etal proteins [41], and many such CCT substrates have recently
been identiﬁed [37–40,42]. If CCT also affects the folding of the
LOX-1 protein, we would predict that reducing the expression of
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showed that the siRNA-mediated knockdown of CCT1 does not sig-
niﬁcantly change the total expression of LOX-1 protein, suggesting
that CCT does not regulate LOX-1 folding or expression. Our results
also showed that CCT1 and LOX-1 colocalize in small, vesicle-like
structures and that OxLDL decreases this association. Further
investigation showed that the vesicles in which CCT1 and LOX-1
colocalize are early and late endosomes. Murphy and colleagues
[15,24] have previously shown that the LOX-1 receptor is constitu-
tively internalized and recycled to the cell surface, independent of
OxLDL, possibly by the endosomal pathway. Although knockdown
of CCT1 did not change overall expression levels of LOX-1 protein,
future work will determine whether membrane turnover and traf-
ﬁcking is dependent on CCT complex function. CCT has also been
reported to participate in the uptake of exogenous antigens and
the presentation of these antigens on both class I and class II major
histocompatibility complex molecules [6,43,44], suggesting a
potential role for the LOX-1/CCT interaction in this process. Under-
standing the physiological relevance of the LOX-1/CCT interaction
requires further analysis and may provide insight into the regula-
tion of LOX-1 function.
An alternatively spliced isoform of LOX-1, termed LOXIN, has
been identiﬁed that lacks exon 5, which is a primary component
of the LOX-1 ligand-binding domain. In LOXIN, the extracellular
dimerization domain and the cytoplasmic domain are intact [29].
LOXIN has been identiﬁed as both a homodimer and as a heterodi-
mer with LOX-1 [28]. The formation of a heterodimer between
LOXIN and LOX-1 reduces OxLDL binding and decreases the cell
surface expression of LOX-1 [28]. It is possible that LOXIN homodi-
mers or LOXIN/LOX-1 heterodimers negatively regulate LOX-1
function by interacting with CCT and competing with or sequester-
ing CCT from LOX-1. Future studies may help determine whether
differential CCT interactions occur with LOXIN homodimers or
LOXIN/LOX-1 heterodimers in intact cells.
In conclusion, we have demonstrated for the ﬁrst time that the
intracellular CCT complex can directly and constitutively interact
with the LOX-1 cytoplasmic domain. A better understanding of this
receptor-proximal molecular association may lead to the identiﬁ-
cation of novel targets for the pharmaceutical intervention of car-
diovascular diseases in which LOX-1 has been implicated, such as
atherosclerosis [4]. Future studies will delineate these interactions
in greater detail and increase our understanding of the role these
interactions play in regulating LOX-1 function under physiologic
and pathologic conditions.
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